SecBot SecBot
Biotech Drug Report Generated Aug 20, 2026

Cosentyx

NVS·NOVARTIS AG
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved (marketed); additional Phase 3 programs completed/terminated
Time to market
Already marketed, approved in the US since January 2015; label-expansion filings for PMR/GCA are possible but no submission or decision date is recorded.
Why 4/10
No hard, dated binary in the next ~12 months: Cosentyx is already approved (original FDA approval Jan 2015) and its remaining Phase 3 expansion programs (polymyalgia rheumatica, giant cell arteritis) are completed with results not yet posted, submissions would be news but no PDUFA/readout date is scheduled, and the drug is one of many products at a mega-cap, so impact caps at 4.
Actionable Insight NEUTRAL

Watch for Novartis disclosures on the completed PMR (381 patients, primary completion Sept 2025) and GCA (354 patients) Phase 3 programs, a regulatory submission for either would be the next meaningful Cosentyx catalyst, though it would move a ~$156 mega-cap modestly. Also track IL-17 competition and any biosimilar entry, plus the next quarterly 6-K for Cosentyx sales trajectory.

Price Chart

Loading chart...

Executive Summary

Cosentyx (secukinumab) is Novartis's (NVS, US-listed) long-approved IL-17A-blocking biologic, a top-selling immunology franchise first cleared by the FDA in January 2015, with subsequent label actions including an Oct 2023 approval catalyst and a March 2025 supplemental approval for the IV formulation. As an already-marketed blockbuster with no scheduled PDUFA or pivotal readout date on the calendar, the drug itself is a stable cash-flow asset rather than a binary catalyst, though two large Phase 3 expansion studies (PMR, 381 patients; GCA, 354 patients) completed in early 2026 with results still unpublished, a potential future label expansion.

How It Works

Cosentyx (secukinumab) is an injected biologic (monoclonal antibody) that targets and neutralizes a specific immune messenger, IL-17A, that drives inflammation in skin and joint diseases such as psoriasis, psoriatic arthritis and ankylosing spondylitis, and which Novartis has been testing in other inflammatory conditions like giant cell arteritis and polymyalgia rheumatica. Blocking that messenger dampens the inflammatory attack.

Trial Status

FDA action records show the original approval (2015-01-21), an approval catalyst in Oct 2023, and a supplemental labeling approval for the IV injectable form (2025-03-12). Novartis Phase 3 trials in polymyalgia rheumatica (NCT05767034, 381 enrolled, completed Feb 2026) and giant cell arteritis (NCT04930094, 354 enrolled, completed Feb 2026; plus a 151-patient GCA-remission study) are COMPLETED with results not yet posted; a Chinese nr-axSpA Phase 3 (137 patients) completed; the thyroid eye disease (28 patients) and rotator cuff tendinopathy (33 patients) Phase 3 studies were TERMINATED.

The Two-Sided Case

▲ Bull Case4
Established commercial franchise: original FDA approval recorded 2015-01-21, plus an Oct 2023 FDA approval catalyst and a March 2025 supplemental approval (labeling) for the IV injectable, evidence of a durable, multi-indication product.
Pipeline optionality: two completed Novartis Phase 3 programs, polymyalgia rheumatica (381 enrolled, completed Feb 2026) and giant cell arteritis (354 enrolled, completed Feb 2026), could support new label expansions if results are positive, extending the product's lifecycle.
Parent is financially deep and diversified: NVS traded at ~$156.24 (2026-08-20) with analyst mean price target of $157.15 and 16 of 34 ratings at Buy/Strong Buy per the latest consensus snapshot, limited single-drug downside risk for holders.
Some institutional accumulation in Q2-2026: JPMorgan added +25.5% to its NVS position, and Citadel and Millennium opened new positions (13F-derived changes).
▼ Bear Case5
No near-term binary: as an approved drug with no scheduled PDUFA/readout, there is little dated upside catalyst; completed PMR/GCA trials have results 'not yet posted' and any submission timing is unannounced.
Mixed expansion record: Phase 3 trials in thyroid eye disease (28 patients) and rotator cuff tendinopathy (33 patients) were TERMINATED, showing the label-expansion strategy does not always pay off.
Competitive erosion risk: the IL-17/inflammation space is crowded (e.g., UCB's bimekizumab was run head-to-head vs secukinumab in a completed 743-patient Phase 3 psoriasis trial) and biosimilar pressure is a standing risk for an aging biologic.
Institutional trimming: in Q2-2026 13F-derived changes, Goldman Sachs trimmed NVS -54.3%, Dodge & Cox went to near_exit (-89.1%), UBS trimmed -33.9% and BMO -59.5%, net ownership signals skew defensive, and analyst recommendation mean is 'hold' (2.83) with only ~2.5% implied upside to the mean target.
High FINRA short-volume flow observed in July-Aug 2026 (55-58% short as a share of off-exchange volume on several days) signals active bearish trading interest, though this is daily flow, not outstanding short interest.

Upcoming Catalysts

  • Publication/presentation of results from the completed Phase 3 PMR (NCT05767034) and GCA (NCT04930094) studies, and any resulting regulatory submissions
  • Next quarterly results (6-K filings) with Cosentyx sales trajectory
  • Any label/regulatory actions for new indications or competitor/biosimilar entries in IL-17 space

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NOVARTIS AG 6-K NVS ·Originating report

Sources · 5

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 sec.gov5 sec.gov